Cadrenal Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.7%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$5.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly2.3MTarget: Sufficient capital to fund Phase 3 clinical trials
Quarterly Net Loss Quarterly-2.5MTarget: Controlled cash burn through disciplined expense management
Stockholders' Equity Quarterly1.8MTarget: Above Nasdaq Capital Market minimum of $2,500,000
Watch Items
- Nasdaq Stockholders' Equity ComplianceTrigger: Stockholders' equity below $2,500,000Action: Utilize ATM equity program and warrant exercises (such as the $2.5 million warrant inducement in April 2026) to restore compliance.
- Going Concern StatusTrigger: Cash runway insufficient for 12 months of operationsAction: Evaluate strategic alternatives, non-dilutive licensing partnerships, or additional public/private equity financing.
- CAD-1005 Phase 3 Trial InitiationTrigger: Finalization of Phase 3 protocol incorporating FDA End-of-Phase 2 feedbackAction: Initiate patient enrollment for the pivotal Phase 3 trial of CAD-1005 in Heparin-Induced Thrombocytopenia (HIT).
- Rare Pediatric Disease Designation (RPDD) for TecarfarinTrigger: FDA decision on RPDD request for Kawasaki diseaseAction: Prepare clinical development plans to leverage potential Priority Review Voucher (PRV) eligibility upon approval.
Research as of 20 Jun 2026